A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week Extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the Treatment of Moderate to Severe Dry Eye Disease
Latest Information Update: 17 Jan 2025
At a glance
- Drugs K 161 (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Kowa Research Institute
Most Recent Events
- 14 Dec 2023 Status changed from active, no longer recruiting to completed.
- 03 May 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2022 Planned End Date changed from 1 Oct 2023 to 1 Jul 2024.